Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 14/20 | 0.74 |
| ▸ | THRB | P10828 | 14/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.72 |
| ▸ | AR | P10275 | 1/20 | 0.72 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890870 | 1.00 | THRA (0.74) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4895566 | 0.92 | THRA (0.65) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4895575 | 0.92 | THRA (0.65) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4891205 | 0.84 | THRA (1.00) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4898557 | 0.84 | THRA (0.63) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4898563 | 0.84 | THRA (0.63) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL5072110 | 0.84 | THRA (0.81) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4898980 | 0.84 | THRA (1.00) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4896873 | 0.83 | THRA (1.00) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL1747240 | 0.81 | FFAR1 (0.72) | FFAR1FFAR4AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | THRA 559/4885THRB 792/4885ESR1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.